Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.
News|Articles|October 8, 2026
September 2026 retina recap: Pivotal readouts and the MOGENRY BLA
Author(s)Kassi Filkins
Pivotal wet AMD, DME, and XLRP readouts; the MOGENRY BLA; and Retina Society, EURETINA, and ESCRS highlights from September.
Advertisement
Advertisement
September was a readout month for retina. Without a single FDA approval in the specialty, the news was driven by topline phase 3 data in wet AMD and DME, a pivotal gene therapy win in X-linked retinitis pigmentosa (XLRP), and the Retina Society 59th Annual Scientific Meeting in Los Angeles (September 23 to 26), where several programs presented their first or longest-term data. The BLA acceptance for
Related to this article
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.
Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.
Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.
Japan's filing covers IRDs broadly, supported by RESTORE and open-label Stargardt data.
Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.
At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.
Advertisement
Advertisement